Articles with the topic: clinical-trial

Huntington's Disease Therapeutics Conference 2024 - Day 3

Huntington's Disease Therapeutics Conference 2024 - Day 3

Dr Rachel Harding, Dr Leora Fox, and Dr Sarah HernandezMarch 07, 2024

Putting it in print: GENERATION HD1 study results published

Putting it in print: GENERATION HD1 study results published

Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an important milestone, and what’s next?

Dr Sarah Hernandez, Dr Rachel Harding, and Dr Leora FoxDecember 07, 2023

Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD

Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD

The HD pipeline is rich and varied. Let's talk about some out-of-the-box approaches for developing drugs for HD that don't involve huntingtin lowering.

Kelly AndrewNovember 24, 2023

Drug to treat movement symptoms of HD approved by FDA

Drug to treat movement symptoms of HD approved by FDA

The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntington’s disease

Dr Leora Fox and Dr Rachel HardingAugust 22, 2023

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Both PTC Therapeutics and uniQure have shared updates from their respective clinical trials, testing different huntingtin-lowering approaches. We explore the data presented from both of these studies and what this means for HD family members.

Dr Leora Fox and Dr Rachel HardingJune 21, 2023

PROOF-HD study of pridopidine ends with negative result

PROOF-HD study of pridopidine ends with negative result

The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease

Professor Ed WildApril 25, 2023

Roche Phase II GENERATION HD2 study underway

Roche Phase II GENERATION HD2 study underway

Roche released a community letter in early 2023, to share that their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. In this article, we summarise the latest news about this huntingtin-lowering drug.

Dr Rachel HardingFebruary 14, 2023

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Novartis have announced that they are ending development of the drug branaplam in Huntington’s disease. Here, we review this latest news and its impact on the HD community.

Dr Rachel HardingDecember 09, 2022

Update on the PTC Therapeutics PIVOT-HD Trial

Update on the PTC Therapeutics PIVOT-HD Trial

Last week, PTC Therapeutics released a statement sharing that recruitment of participants into the US arm of the PIVOT-HD trial has been paused. In this article, we will lay out exactly what is known and what this announcement means.

Dr Rachel Harding and Dr Leora FoxNovember 03, 2022